|
1
|
Lengauer C, Kinzler KW and Vogelstein B:
Genetic instabilities in human cancers. Nature. 6712:643–649. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Loeb LA: A mutator phenotype in cancer.
Cancer Res. 61:3230–3239. 2001.PubMed/NCBI
|
|
3
|
D’Assoro AB, Lingle WL and Salisbury JL:
Centrosome amplification and the development of cancer. Oncogene.
21:6146–6153. 2002.
|
|
4
|
Jin S and Levine AJ: The p53 functional
circuit. J Cell Sci. 114:4139–4140. 2001.PubMed/NCBI
|
|
5
|
D’Assoro AB, Busby R, Suino K, Delva E,
Almodovar-Mercado GJ, Johnson H, Folk C, Farrugia DJ, Vasile V,
Stivala F and Salisbury JL: Genotoxic stress leads to centrosome
amplification in breast cancer cell lines that have an inactive
G1/S cell cycle checkpoint. Oncogene. 23:4068–4075. 2004.PubMed/NCBI
|
|
6
|
D’Assoro AB, Busby R, Acu ID, Quatraro C,
Reinholz MM, Farrugia DJ, Schroeder MA, Allen C, Stivala F, Galanis
E and Salisbury JL: Impaired p53 function leads to centrosome
amplification, acquired ERalpha phenotypic heterogeneity and
distant metastases in breast cancer MCF-7 xenografts. Oncogene.
27:3901–3911. 2008.PubMed/NCBI
|
|
7
|
Brinkley BR: Managing the centrosome
numbers game: from chaos to stability in cancer cell division.
Trends Cell Biol. 11:18–21. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
D’Assoro AB, Barrett SL, Folk C, Negron
VC, Boeneman K, Busby R, Whitehead C, Stivala F, Lingle WL and
Salisbury JL: Amplified centrosomes in breast cancer: a potential
indicator of tumor aggressiveness. Breast Cancer Res Treat.
75:25–34. 2002.PubMed/NCBI
|
|
9
|
Lingle WL, Lutz WH, Ingle JN, Maihle NJ
and Salisbury JL: Centrosome hypertrophy in human breast tumors:
implications for genomic stability and cell polarity. Proc Natl
Acad Sci USA. 95:2950–2955. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lingle WL, Barrett SL, Negron VC, D’Assoro
AB, Boeneman K, Liu W, Whitehead CM, Reynolds C and Salisbury JL:
Centrosome amplification drives chromosomal instability in breast
tumor development. Proc Natl Acad Sci USA. 99:1978–1983. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tarapore P and Fukasawa K: Loss of p53 and
centrosome hyperamplification. Oncogene. 21:6234–6240. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meraldi P, Lukas J, Fry AM, Bartek J and
Nigg EA: Centrosome duplication in mammalian somatic cells requires
E2F and Cdk2-cyclin A. Nat Cell Biol. 1:88–93. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okuda M: The role of nucleophosmin in
centrosome duplication. Oncogene. 21:6170–6174. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mussman JG, Horn HF, Carroll PE, Okuda M,
Tarapore P, Donehower LA and Fukasawa K: Synergistic induction of
centrosome hyperamplification by loss of p53 and cyclin E
overexpression. Oncogene. 19:1635–1646. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nikonova AS, Astsaturov I, Serebriiskii
IG, Dunbrack RL Jr and Golemis EA: Aurora A kinase (AURKA) in
normal and pathological cell division. Cell Mol Life Sci. Aug
3–2012.(Epub ahead of print).
|
|
16
|
Li JJ, Weroha SJ, Lingle WL, Papa D,
Salisbury JL and Li SA: Estrogen mediates Aurora-A overexpression,
centrosome amplification, chromosomal instability, and breast
cancer in female ACI rats. Proc Natl Acad Sci USA. 101:18123–18128.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Staff S, Isola J, Jumppanen M and Tanner
M: Aurora-A gene is frequently amplified in basal-like breast
cancer. Oncol Rep. 23:307–312. 2010.PubMed/NCBI
|
|
18
|
Yang H, He L, Kruk P, Nicosia SV and Cheng
JQ: Aurora-A induces cell survival and chemoresistance by
activation of Akt through a p53-dependent manner in ovarian cancer
cells. Int J Cancer. 119:2304–2312. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
D’Assoro AB, Leontovich A, Amato A,
Ayers-Ringler JR, Quatraro C, Hafner K, Jenkins RB, Libra M, Ingle
J, Stivala F, Galanis E and Salisbury JL: Abrogation of p53
function leads to metastatic transcriptome networks that typify
tumor progression in human breast cancer xenografts. Int J Oncol.
37:1167–1176. 2010.PubMed/NCBI
|
|
20
|
Leontovich AA, Zhang S, Quatraro C, Iankov
I, Veroux PF, Gambino MW, Degnim A, McCubrey J, Ingle J, Galanis E
and D’Assoro AB: Raf-1 oncogenic signaling is linked to activation
of mesenchymal to epithelial transition pathway in metastatic
breast cancer cells. Int J Oncol. 40:1858–1864. 2012.PubMed/NCBI
|
|
21
|
Pinto AE, André S, Mendonça E, Silva G and
Soares J: Overall survival in advanced breast cancer: relevance of
progesterone receptor expression and DNA ploidy in fine-needle
aspirates of 392 patients. Int J Biol Markers. 18:7–12.
2003.PubMed/NCBI
|
|
22
|
Duensing S and Münger K: Centrosomes,
genomic instability, and cervical carcinogenesis. Crit Rev Eukaryot
Gene. 13:9–23. 2003. View Article : Google Scholar
|
|
23
|
Levine AJ, Momand J and Finlay CA: The p53
tumour suppressor gene. Nature. 351:453–456. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kronenwett U, Castro J, Roblick UJ,
Fujioka K, Ostring C, Faridmoghaddam F, Laytragoon-Lewin N,
Tribukait B and Auer G: Expression of cyclins A, E and
topoisomerase II alpha correlates with centrosome amplification and
genomic instability and influences the reliability of cytometric
S-phase determination. BMC Cell Biol. 4:82003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lukasiewicz KB, Greenwood TM, Negron VC,
Bruzek AK, Salisbury JL and Lingle WL: Control of centrin stability
by Aurora A. PLoS One. 6:e212912011. View Article : Google Scholar : PubMed/NCBI
|
